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Background: The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their
presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple
sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study
to assess the association between response to IFNβ, NAb and fatigue.
Methods: Patients with relapsing-remitting MS on IFNβ treatment were included. During the second year of
treatment, the patients were analyzed for NAb status and non-response criteria to IFNβ (number of relapses ≥1
during the follow-up period, increase in the Expanded Disability Status Scale ≥0.5). The score on the Modified
Fatigue Impact Scale (MFIS pathological if score ≥35) was noted for each patient.
Results: Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and
57.4% had a pathological MFIS score. Fatigue was increased in NAb + patients (p = 0.0014) and they were more
likely to present non-response criteria to IFNβ (p = 0.041) than NAb- patients. Multivariate logistic regression analysis
showed that the presence of NAb was related to fatigue (p = 0.0032) and denoted disease activity in these patients
(p = 0.026).
Conclusions: This study demonstrates the impact of NAb on the non-clinical response to IFNβ. Fatigue assessment
is an indicator of IFNβ responsiveness and a predictive biomarker of deterioration on patient’s neurological status.
Keywords: Multiple sclerosis, Neutralizing antibodies, Fatigue, Interferon-beta, Response to treatmentBackground
Immunomodulatory treatment with interferon-beta (IFNβ)
is a first-line treatment for patients with relapsing-
remitting multiple sclerosis (MS). As with any therapy de-
rived from human recombinant proteins, this treatment
has immunogenic properties [1]. Neutralizing antibodies
(NAb) against IFNβ develop in 2% to 46% of treated pa-
tients [2-14]. This large variability in observed NAb pre-
valence can be explained by the more immunogenic
character of IFNβ-1b compared with IFNβ-1a [13], the
increased prevalence of NAb with multi-weekly injec-
tions [9], the more immunogenic nature of subcutaneous* Correspondence: manceau2@wanadoo.fr
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unless otherwise stated.administration as opposed to intramuscular administra-
tion [8,13,14], the dose treatment [7,11] and the different
follow-up durations. Moreover, a positive NAb status may
be reversible over time [12,13,15]. The origin of the re-
versibility of NAb status is unknown but the hypothesis of
a re-establishment of immune tolerance after a breakdown
period with IFNβ-treatment is possible [16]. While it is
recognized that NAb has a negative impact on magnetic
resonance imaging (MRI), the effect of NAb on clinical
outcome remains a subject of debate to this day. Indeed,
some studies have found conflicting results regarding the
impact of NAb on the clinical response to IFNβ
[2,4,5,8-12,14,17,18]. The variability of the results about
the impact of NAb may depend on the statistical ap-
proaches used in these studies, which should consider that
many of the NAb positive patients revert to a NAbal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Manceau et al. BMC Neurology 2014, 14:215 Page 2 of 9
http://www.biomedcentral.com/1471-2377/14/215negative status over time [19]. Another factor, that can im-
pact on NAb status is the neutralizing assay used in these
different studies [19]. The interpretation of the NAb status
is consequently difficult for the clinician to analyze. This
has given rise to recommendations aimed at facilitating
the decision as to whether to test for NAb or not [19].
Fatigue is a symptom reported by 53-92% of patients
with MS and is one of its most disabling symptoms
[20-23]. Direct involvement of immunological factors
has been suggested as a pathophysiological mechanism
responsible for fatigue during MS [24,25]. Moreover, the
intensity of fatigue (physical and psychosocial fatigue),
was statistically correlated with the EDSS (Expanded
Disability Status Scale) and physical fatigue was a prog-
nostic marker of a worsening of the disability status after
a follow-up period of three years [26,27].
We hypothesized that fatigue could be predictive of
non-response to treatment with IFNβ. Accordingly, we
studied the association between response to IFNβ, fa-
tigue and the presence of NAb.
Methods
Inclusion criteria
To be included patients had to be ≥18 years, IFNβ naive,
with an EDSS ≤5.0, and fulfilling the clinical criteria for
treatment with IFNβ, i.e., patients with a clinically isolated
syndrome (CIS) with an active inflammatory process se-
vere enough to need intravenous corticosteroids, if alter-
native diagnoses had been excluded, and if these patients
were considered at high risk of developing clinically de-
finite MS, or patients with relapsing-remitting MS with at
least two relapses within the last two years [28].
Study design
This was a prospective, multicentre study, in the neuro-
logical department of three hospitals in France: Strasbourg,
Rennes and Nancy. Patients fulfilling the inclusion criteria
underwent two specific consultations. The initial consult-
ation, called the “inclusion consultation”, was performed
when IFNβ was initiated. During this inclusion consul-
tation, patient consent was obtained and the pre-IFNβ
EDSS was assessed. The choice of the IFNβ was at
the discretion of the clinician: intramuscular IFNβ-1a
(Avonex®, Biogen Idec, Cambridge, MA, USA), sub-
cutaneous IFNβ-1a (22 or 44 μg REBIF®, Merck Serono,
Geneva, Switzerland), subcutaneous IFNβ-1b (BETA-
FERON®, Bayer Schering, Berlin, Germany; EXTAVIA®,
Novartis, Dorval, Canada). A second consultation, called
the “follow-up consultation”, was used to assess the cli-
nical response to IFNβ, the fatigue experienced, the seve-
rity of the flu-like syndrome and the patient’s mood. This
“follow-up consultation” happened during the second year
of treatment. This time for this consultation was chosen
to systematically test patients for NAb, as recommendedby the experts panel recommendations [19]. During this
“follow-up” consultation, patients and physicians were not
aware of the result of NAb status. A written informed
consent for participation in the study was obtained from
all patients. Because the protocol of this study did not
modify the classical clinical practice, it was not necessary,
in accordance with the French law at the beginning of the
study, to require the approval of a specific medical
ethic committee. Nevertheless, this study was approved
by the Neurology Department of Nancy University
Hospital and was conducted according to the criteria of
the Helsinki Declaration. Moreover, the use of the
database was approved by the CNIL (Commission
Nationale de l’Informatique et des Libertés – National
Commission on Information Technology and Liberties)
and the CCTIRS (Comité Consultatif sur le Traitement de
l’Information en matière de Recherche dans le domaine
de la Santé – Consultative Committee on Clinical Re-
search Data Management).
Evaluation of response to IFNβ treatment
The response to IFNβ was assessed at a clinical level
only. Non-response to IFNβ between the inclusion and
follow-up consultations was defined as the occurrence of
at least one MS relapse and/or an increase in EDSS ≥0.5,
confirmed after six months. A MS relapse was defined
as the occurrence, the recurrence or the worsening for
more than 24 hours of neurological symptoms and usu-
ally ending in a partial or complete remission [29,30]. A
patient was considered to be an IFNβ responder if there
was no relapse or worsening of EDSS during follow-up
period.
Evaluation of fatigue
Fatigue was assessed during the follow-up consultation
with the French version of the MFIS [23,31]. The MFIS
is a self-administered questionnaire, validated in French,
which explores fatigue experienced during the previous
four weeks through a set of 21 items. Each item is
marked from zero (“never”) to four (“almost always”).
The final score thus ranges from zero to 84. In our
study, a patient was considered tired if his MFIS score
was ≥35.
Evaluation of the severity of the flu-like syndrome
Under IFNβ, fatigue may be secondary to the flu-like syn-
drome. Consequently, the flu-like syndrome was also eval-
uated in this study, using items 13 to 16 from the MSTCQ
(Multiple Sclerosis Treatment Concern Questionnaire)
[32]. The MSTCQ is a self-administered questionnaire
assessing the overall tolerability of IFNβ. Items 13–16 as-
sess more specifically the flu-like syndrome. Each of these
four items is marked from zero to five. The final score
thus ranges from zero to 20.
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As a depressive syndrome can be correlated with fatigue
during MS, we also assessed mood [26]. For this we used
the MADRS (Montgomery and Asberg Depression Rat-
ing Scale) which is a hetero-administered questionnaire
consisting of 10 items, marked from zero to six and vali-
dates in French [33,34]. The final score thus ranges from
zero to 60.
Testing for neutralizing antibodies against IFNβ
NAb testing was systematically carried out by the hormo-
nology department of the University Hospital of Rennes
using a method called “Luciferase Reporter Gene Assay”
[35]. NAb titers were calculated using the Kawade-
Grossberg formula in TRU (Ten fold Reduction neutra-
lizing Unit)/mL [36]. A titer just under 20 TRU/mL was
considered negative; between 20 and 100 TRU/mL and
20 to 400 TRU/mL weakly to moderately positive for
IFNβ-1a and IFNβ-1b respectively; and over 100 TRU/mL
and 400 TRU/mL highly positive for IFNβ-1a and IFNβ-1b
respectively. There was no other NAb testing to confirm
NAb positive status.
Statistical analyses
All statistical analyses were performed using the SAS 9.2®
software. All figures were created using GraphPad Prism 5®.
Bivariate analyses were expressed as mean difference +/−
SEM (Standard Error Mean). The quantitative variables
were compared by Student t-test or Man-Whitney test
and qualitative variables by chi-square test or Fisher’s
exact test. The correlation between variables was deter-
mined by calculating the Spearman coefficient. The multi-
variate analysis, to eliminate confounding factors, used
logistic regression models. This model was preferred to a
survival model because all data were available and col-
lected on the anniversary date of 2 years precisely. A
p < 0.05 was considered statistically significant.
Results
Included patient characteristics
In all 176 patients fulfilled the inclusion criteria and par-
ticipated in this study: 131 (74.4%) were females, 45
(25.6%) were males giving a sex ratio of 2.91. The average
age at MS diagnosis was 34 +/− 0.8 years and at study in-
clusion 36 +/− 0.8 years. The mean duration of MS course
before inclusion was 5.3 +/− 0.4 years. The mean EDSS at
introduction of IFNβ was 1.7 +/− 0.1 and the mean num-
ber of relapses before treatment 2.4 +/− 0.1. At inclusion
consultation, 51 patients were CIS with only one MS re-
lapse. The median time from the inclusion consultation to
the follow-up consultation was 411 days. Twenty-eight pa-
tients (16.1%) received intramuscular IFNβ-1a, 47 (27%)
subcutaneous IFNβ-1b and 99 (56.9%) subcutaneous
IFNβ-1a. Thirty-nine patients (22.3%) had developed apositive NAb status (NAb+) in the second year of
treatment. Ninety-six patients (54.5%) were classified as
non-responders to IFNβ between the two consultations
(relapse ≥1 or ΔEDSS ≥0.5) and 101 patients (57.4%) were
tired at the follow-up consultation.
NAb + patients characteristics
The 39 NAb + patients were compared with the 136 pa-
tients who remained NAb- during follow-up (Table 1).
Both groups of patients were similar in terms of age at MS
diagnosis (NAb-: 33.8 +/− 0.9 years vs. NAb+: 35.2 +/−
1.5 years, p = 0.48, Student t-test), age at treatment initi-
ation (35.5 +/− 0.9 years vs. 37.3 +/− 1.6 years, p = 0.32,
Student t-test), duration of disease progression (5.3 +/−
0.5 years vs. 4.9 +/− 0.9 years, p = 0.66, Student t-test),
EDSS at inclusion consultation (1.7 +/− 0.1 vs. 1.8 +/− 0.2,
p = 0.66, Student t-test) and number of relapses before in-
clusion consultation (2.4 +/− 0.1 vs. 2.4 +/− 0.2, p = 0.98,
Student t-test). There was also no statistically significant
difference between the two groups regarding the IFNβ
type (intramuscular IFNβ-1a: 25 (18.5%) vs. 3 (7.9%)
patients; subcutaneous IFNβ-1a: 77 (57%) vs. 22 (57.9%)
patients; subcutaneous IFNβ-1b SC: 33 (24.4%) vs. 13
(34.2%) patients, p = 0.21, Fisher’s exact test). In contrast,
there was a statistically significant difference in terms of
sex with an F/M sex ratio of 2.32 in the NAb- group vs.
8.75 in the NAb + group (p = 0.012, Fisher’s exact test).
Relationship between NAb titer and clinical response to
IFNβ
We compared the NAb- group with the NAb + group and
studied the impact of NAb on the response to IFNβ. On
bivariate analysis, we found a statistically significant differ-
ence during the follow-up period in terms of number of re-
lapses (NAb-: 0.6 +/− 0.1 vs. NAb + 1.0 +/− 0.2, p = 0.016,
Student t-test) and EDSS variation (ΔEDSS = 0.1 +/− 0.1
vs. 0.4 +/− 0.1, p = 0.035, Student t-test) (Figure 1a and b).
Thus, the ratio Responder/Non-Responder to IFNβ is sta-
tistically different between the two groups (Responder/
Non-Responder: 67/69 (49.3%/50.7%) vs. 12/27 (30.8%/
69.2%), p = 0.041, Chi-square test) (Figure 1c).
Multivariate analysis demonstrated that non-response
to IFNβ is the only factor explaining a NAb + status
(OR = 2.4, 95% CI: 1.1-5.3; p = 0.026).
NAb impact on the different scales
Bivariate analysis showed a trend for NAb + patients to
have a higher MADRS score (4.8 +/− 0.7) than NAb- pa-
tients (3.6 +/− 0.4; p = 0.14; Student t-test) (Figure 2a).
NAb + patients tend to be less affected than NAb- patients
by the flu-like syndrome as assessed by items 13 to 16 of
the MSTCQ (5.9 +/− 0.8 vs. 7.2 +/− 0.4; p = 0.086; Student
t-test) (Figure 2b). In terms of fatigue on the MFIS score,
there was a significant difference between the NAb- group
Table 1 Comparison of the different variables between NAb- and NAb + patients
NAb- (n = 136) NAb + (n = 39) p
Female sex 95 (69.9%) 35 (89.7%) 0.012
Mean age at MS diagnosis (years +/− SEM) 33.8 +/− 0.9 35.2 +/− 1.5 0.48
Mean age at treatment initiation (years +/− SEM) 35.5 +/− 0.9 37.3 +/− 1.6 0.32
Mean duration of MS course (years +/− SEM) 5.3 +/− 0.5 4.9 +/− 0.9 0.66
Mean EDSS at inclusion consultation (+/− SEM) 1.7 +/− 0.1 1.8 +/− 0.2 0.66
Mean ΔEDSS* (+/− SEM) +0.1 +/− 0.1 +0.4 +/− 0.1 0.035
Mean number of relapse before inclusion consultation (+/− SEM) 2.4 +/− 0.1 2.4 +/− 0.2 0.98
Mean number of relapse between inclusion and follow-up consultations (+/− SEM) 0.6 +/− 0.1 1.0 +/− 0.2 0.016
Number of non-responder patients 69 (50.7%) 27 (69.2%) 0.041
Mean MFIS score (+/− SEM) 34.2 +/− 1.7 47.3 +/− 2.9 0.0002
Number of fatigue patients 69 (50.7%) 31 (79.5%) 0.0014
Mean MADRS score (+/− SEM) 3.6 +/− 0.4 4.8 +/− 0.7 0.14
Mean MSTCQ score (+/− SEM) 7.2 +/− 0.4 5.9 +/− 0.8 0.086
IFNβ type:
- Intramuscular IFNβ-1a 25 (18.5%) 3 (7.9%) 0.21
- Subcutaneous IFNβ-1a 77 (57%) 22 (57.9%)
- Subcutaneous IFNβ-1b 33 (24.4%) 13 (34.2%)
*ΔEDSS = EDSS at the follow-up consultation – EDSS at the inclusion consultation.
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p = 0.0002; Student t-test) (Figure 2c). Also, the ratio No
fatigue patients/Fatigue patients was significantly different
between the NAb- group (67/69) and the NAb + group
(8/31; p = 0.0014, Chi-square test) (Figure 2d).
Relationship between response to IFNβ and fatigue
Bivariate analysis did not reveal any significant differences
but only a clear tendency for fatigue patients to be non-
responders to IFNβ (Responder/Non-Responder: 41/60
(40.6%/59.4%)) compared with patients without fatigue
(39/36 (52.0%/48.0%); p = 0.13; Chi-square test) (Figure 3).
NAb titer and fatigue intensity
Among the 39 NAb + patients, the mean NAb titer was
878 +/− 346 TRU/mL. Our study did not reveal anyNa
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Figure 1 Comparison of NAb- and NAb + groups in terms of response
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c. Number of responder and non responder in NAb- and NAb + groups. *p <correlation between the NAb titer and MFIS score
(Spearman coefficient r = 0.14; p = 0.38) (Figure 4a).
Fourteen patients (35.9%) were classified as weakly or
moderately positive and 25 patients (64.1%) had a strong
positive titer. The mean MFIS score for patients with a
low to moderate positive titer was statistically similar
to the score for patients with a strong positive titer
(respectively 47.5 +/− 4.7 and 47.2 +/− 3.8; p = 0.98;
Man-Whitney test) (Figure 4b).
A positive NAb titer is related to female sex and fatigue
and is inversely related to the intensity of flu-like
syndrome
Multivariate analysis demonstrated a statistically significant
association between NAb + and fatigue (OR = 4.6; 95% CI:
1.7 to 12.8; p = 0.0032). There was also a statisticallyNa
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Figure 2 Comparison between NAb- and NAb + groups on the different scales at the time of the follow-up consultation. a. Mean
MADRS score at follow-up consultation between NAb- and NAb + groups. b. Mean MSTCQ score at follow-up consultation between NAb- and
NAb + groups. c. Mean MFIS score at follow-up consultation between NAb- and NAb + groups. d. Number of fatigue and no fatigue in NAb- and
NAb + groups. **p <0.01, ***p <0.001.
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(OR = 3.4; 95% CI: 1.05 to 11.0; p = 0.04). Moreover, the in-
tensity of the flu-like syndrome was inversely correlated to
the probability of developing a NAb + titer (OR = 0.88; 95%
CI: 0.80-0.97; p = 0.01).
CIS subgroup of patients
Among the 51 CIS patients at inclusion consultation, 23
(45.1%) converted into a clinically definite MS. These 23
patients were compared to the 28 CIS patients without
conversion to a clinically definite MS. There was no sta-
tistically significant difference between these two groups
in terms of Nab status, EDSS score, fatigue, depression
and flu-like syndrome intensity (Table 2).
Discussion
Our study demonstrates the impact of NAb on the non-
clinical response to IFNβ in relapsing-remitting MS
patients. The clinical impact is characterized both by the
existence of relapses during follow-up and by the wors-
ening of EDSS at the end of the follow-up period. Our
hypothesis that fatigue could be predictive of a dete-
rioration of the patient’s neurological status can beNo
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Figure 3 Comparison of No fatigue and Fatigue groups in terms
of response to IFNβ treatment.tentatively confirmed. Nevertheless, this hypothesis is
supported by the demonstration of a link between the
presence of NAb and fatigue, NAb being involved in
non-response to IFNβ. In addition, our study suggests
that women are at greater risk of developing NAb. We
show that the presence of the flu-like syndrome during
follow-up is predictive for the absence of NAb.
The non-response to IFNβ in these patients reflects
both the number of relapses during follow-up and chan-
ges in EDSS. To our knowledge, only one study to date
has demonstrated the negative role of these two clinical
parameters but this study only included 78 patients [10].
Other studies have found divergent results and are sum-
marized in Table 3 [2,4,5,8-12,14,17,18].
These differences in results can be explained by meth-
odological differences from one study to another, espe-
cially in the duration of the follow-up period. The median
follow-up of patients in our study was 411 days which is a
short follow-up duration. Thus, it could be envisaged that
the clinical impact of NAb on the non-response to IFNβ
is expressed mainly at the beginning of treatment and that
the negative clinical impact of NAb would tend to de-
crease over time. This hypothesis is supported by the
possibility of a NAb reversibility [12,13,15]. However, we
can conclude that the presence of NAb is a marker for
therapeutic ineffectiveness to IFNβ at the beginning of
treatment.
The various IFNβ available for the clinician have diffe-
rent immunogenicity properties [7-9,11,13,14]. In terms of
non-response to IFNβ induced by NAb, our study would
point towards the use of the least immunogenic IFNβ, i.e.,
intramuscular IFNβ-1a. To our knowledge, no study has
compared the therapeutic response to the different forms
of IFNβ on the annualized relapse rate and EDSS progres-
sion, except the work of Etemadifar et al. which was on a
small population of 90 patients [37]. In the same vein, our
study found that the risk of developing NAb was higher
for women than for men. This finding could suggest a bet-
ter clinical response to IFNβ in male patients. Few studies
have focused on the clinical response to IFNβ according
to gender. One study, by Rudick et al., found no difference
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women but this result may be biased due to the low preva-
lence of NAb in the study as intramuscular IFNβ-1a is the
least immunogenic IFNβ [38].
Fatigue could be the sign of a negative clinical course
of MS and may even be the only manifestation of an au-
thentic relapse [39]. In our work, we found a clear trend
for non-responder patients to IFNβ to be more tired
than responder patients. It has already been suggested inTable 2 Comparison of the different variables on CIS patients
the end of follow-up period
CIS patients with
to clinically defin
Female sex 17 (73.9%)
Mean age at MS diagnosis (years +/− SEM) 31.8 +/− 2.2
Mean age at treatment initiation (years +/− SEM) 33.4 +/− 2.5
Mean EDSS at inclusion consultation (+/− SEM) 1.2 +/− 0.2
Mean ΔEDSS* (+/− SEM) +0.2 +/− 0.04
Mean MFIS score (+/− SEM) 36.0 +/− 4.5
Number of fatigue patients 13 (56.5%)
Mean MADRS score (+/− SEM) 3.7 +/− 0.8
Mean MSTCQ score (+/− SEM) 6.3 +/− 0.8
Number of NAb + patients 5 (21.7%)
IFNβ type:
- Intramuscular IFNβ-1a 2 (8.7%)
- Subcutaneous IFNβ-1a 16 (69.6%)
- Subcutaneous IFNβ-1b 5 (21.7%)
*ΔEDSS = EDSS at the follow-up consultation – EDSS at the inclusion consultation.the past that fatigue is a prognostic marker for an un-
favorable neurological outcome [27]. We demonstrate a
highly significant relation between fatigue and Nab + sta-
tus. As Nab + status is related to non-response to IFNβ,
we believe that fatigue is a clinical marker for non-
response to IFNβ. Thus, it would seem appropriate to
propose that tired patients under IFNβ be tested for
NAb and, if a NAb + status is detected, to consider an
alternative therapy. Thereby, in 2008, Capobianco et al.with or without conversion to clinically definite MS at
conversion
ite MS (n = 23)
CIS patients without conversion
to clinically definite MS (n = 28)
p
21 (75%) 0.93
31.0 +/− 2.0 0.79
32.1 +/− 2.0 0.69
1.3 +/− 0.2 0.77
0 +/− 0.02 0.70
35.8 +/− 3.3 0.98
16 (57.1%) 0.96
3.2 +/− 0.5 0.63
6.3 +/− 0.9 0.99
7 (25.0%) 0.78
3 (10.7%) 0.43
15 (53.6%)
10 (35.7%)
Table 3 Summary of the literature on clinical impact of NAb in terms of annualized relapse rate, EDSS and MRI activity
Study Annualized relapse rate
(Number of relapses/year)
EDSS score
impact
MRI
impact
Study
duration
NAb+ NAb- p
IFNβ Multiple Sclerosis Study Group, University of British
Columbia MS/MRI Analysis Group, Neurology 1996 [2]
1.16 0.50 < 0.05 Positive impact Yes 3 years
Ruddick et al., Neurology 1998 [4] 0.50 0.65 NS No impact Yes 2 years
PRISMS Study Group, Lancet 1998 [5] 1.75 1.74 _ _ _ 2 years
Panitch et al., Neurology 2002 [8] _ _ NS _ Yes 48 weeks
Sorensen et al., Lancet 2003 [9] 0.64 0.43 < 0.03 No impact _ _
Malucchi et al., Neurology 2004 [10] 0.85 0.53 0.039 Negative impact _ 3 years
Francis et al., Neurology 2005 [17] 0.85 0.52 < 0.001 No impact Yes 4 years
Kappos et al., Neurology 2005 [18] 0.97 0.70 0.04 No impact Yes 4 years
Freedman et al., Multiple Sclerosis 2005 [11] _ _ NS No impact Yes 3 years
Hartung et al., Neurology 2011 [12] _ _ 0.39 No impact Yes 5 years
Sato et al., Tokohu J Exp Med 2012 [14] _ _ 0.13 _ Yes _
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glatiramer acetate in NAb + patients with a gain of
20.1 months without relapse in this setting [40]. Our
work demonstrates that the intensity of fatigue is not
correlated to the value of the NAb titer. Thus, in the hy-
pothesis that fatigue is a reflection of non-response to
IFNβ treatment, a high NAb titer would not denote a
poorer clinical response than a low or a moderate titer.
Nevertheless, this study demonstrates that fatigue can
also occur in patients with NAb negative status. It leads
to consider that fatigue during MS is not only related
with NAb status. Indeed, there are several dimensions to
MS-related fatigue [41,42]. Primary fatigue is directly re-
lated to the pathophysiological mechanisms associated
with MS, including direct involvement of immunological
factors [24,25]. Secondary fatigue is explained by the
direct effects of the disease (sleep disorder, reactive de-
pression, analgesic treatment of nociceptive pain, etc.).
Interestingly, the occurrence of the flu-like syndrome
under IFNβ seems to be prognostic for NAb- status. In-
deed, the intensity of the flu-like syndrome is inversely
correlated to the risk of being NAb+. The flu-like syn-
drome is one of the major causes for patients to stop a
long-term IFNβ treatment. Hartung et al. found a similar
result in their study: a clear trend in NAb- patients to stop
their treatment with IFNβ compared with NAb + patients
due to the adverse effects of the treatment which were
more prevalent in the former [12]. Therefore, the exis-
tence of a flu-like syndrome during the follow-up of pa-
tients receiving IFNβ is a good prognostic factor for the
absence of NAb and, paradoxically, would suggest that
treatment should be maintained. However, this result
should be interpreted with caution because the flu-like
syndrome in our study was assessed by a subset of theMSTCQ-score. This score, though validated to assess the
overall adverse effects of a treatment with IFNβ, has not
yet been validated for all the subsets.
Our study has some limitations. Firstly, this work has
an open non randomized study design that may in-
fluence the results and lead to a selection bias. Further-
more, the work focuses on a relatively small population
of 176 patients with a median follow-up just under
14 months. These two parameters give our study a low
statistical power to clearly demonstrate a significant rela-
tion between fatigue and non-response to IFNβ. The link
between fatigue and adverse neurological outcome in
the work of Debouverie et al. was demonstrated after a
3-year follow-up [27]. We believe that a longer follow-
up on a larger population would allow us to confirm this
correlation. In addition, non-response to IFNβ can also
be evaluated radiologically and not only clinically. It is
possible that some of our patients who were considered
IFNβ responders could have a radiological activity of the
disease. This might be a bias in our study in the classifi-
cation of patients. Moreover, it would be interesting to
know for NAb + patients the time period spent with
NAb- status, that can also impact the interpretation of
the results [19].
Conclusion
Our study establishes the impact of NAb on the non-
response to IFNβ in patients with relapsing-remitting MS.
Moreover, there is a tripartite relation between response
to IFNβ, fatigue and NAb status. NAb positive status is
correlated with an increased prevalence of fatigue during
follow-up. Although the link between fatigue and non-
response to IFNβ cannot be demonstrated directly be-
cause of a lack of statistical power, we found a clear trend
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http://www.biomedcentral.com/1471-2377/14/215to suggest a link between these two parameters. Thus,
fatigue in patients treated with IFNβ constitutes a good
clinical marker for non-response to treatment. Detection
of fatigue by a validated scale should lead the clinician to
test for NAb status and possibly to propose an alternative
therapeutic treatment to IFNβ.
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